Genmab A/S, of Copenhagen, Denmark, offered additional data from the interim analysis of the Arzerra (ofatumumab) phase III study, PROLONG (OMB112517). The study evaluated ofatumumab maintenance therapy vs. no further treatment (observation) in patients with a complete response or partial response after second- or third-line treatment for chronic lymphocytic leukemia.